XTL Biopharmaceuticals Ltd. (XTLB)
NASDAQ: XTLB · Real-Time Price · USD
0.850
-0.023 (-2.67%)
At close: Dec 5, 2025, 4:00 PM EST
0.850
+0.000 (0.01%)
After-hours: Dec 5, 2025, 5:49 PM EST
XTL Biopharmaceuticals Revenue
In the year 2024, XTL Biopharmaceuticals had annual revenue of $451.00K. XTL Biopharmaceuticals had revenue of $405.00K in the quarter ending December 31, 2024.
Revenue (ttm)
$451.00K
Revenue Growth
n/a
P/S Ratio
18.09
Revenue / Employee
$45,100
Employees
10
Market Cap
8.16M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
XTLB News
- 8 months ago - XTL Names Mr. Noam Band as its New Chief Executive Officer - GlobeNewsWire
- 1 year ago - XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million - GlobeNewsWire
- 1 year ago - XTL Entered Definitive Agreement to Acquire The Social Proxy - GlobeNewsWire
- 1 year ago - XTL To Aquire The Social Proxy - GlobeNewsWire
- 2 years ago - XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel - GlobeNewsWire
- 2 years ago - XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - GlobeNewsWire
- 4 years ago - Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting - PRNewsWire